Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy
Real‐world outcomes of daratumumab monotherapy (DM) for relapsed/refractory multiple
myeloma (RRMM) have remained unclear. We conducted a multicentre retrospective study …
myeloma (RRMM) have remained unclear. We conducted a multicentre retrospective study …
Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory …
PL Clemens, X Yan, HM Lokhorst, S Lonial… - Clinical …, 2017 - Springer
Daratumumab is a CD38 monoclonal antibody recently approved for the treatment of
multiple myeloma (MM). We report daratumumab pharmacokinetic data from GEN501, a …
multiple myeloma (MM). We report daratumumab pharmacokinetic data from GEN501, a …
Daratumumab granted breakthrough drug status
JP Laubach, YT Tai, PG Richardson… - Expert opinion on …, 2014 - Taylor & Francis
Multiple myeloma (MM) remains incurable despite important recent advances in treatment
due to its inherent resistance, characterized by highly complex and heterogeneous …
due to its inherent resistance, characterized by highly complex and heterogeneous …
[HTML][HTML] Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma
Introduction: Daratumumab (DARA) is a novel human monoclonal antibody that targets
CD38, a protein that is highly expressed on multiple myeloma (MM) cells. DARA acts …
CD38, a protein that is highly expressed on multiple myeloma (MM) cells. DARA acts …
CD38 expression loss in multiple myeloma treated with daratumumab
N Hotchandani, H Fung, E Dulaimi - American Journal of …, 2016 - academic.oup.com
Daratumumab is a new immunotherapeutic agent, approved for the treatment of double
refractory multiple myeloma patients. It is a human monoclonal antibody against CD38 …
refractory multiple myeloma patients. It is a human monoclonal antibody against CD38 …
[HTML][HTML] A phase 2 trial of daratumumab and pembrolizumab in refractory multiple myeloma
B Paul, J Symanowski, P Osipoff, S Norek, AP Ndiaye… - Blood, 2020 - Elsevier
Background: Despite significant advances in the treatment of multiple myeloma (MM), it
remains an incurable malignancy and novel treatments are still desperately needed …
remains an incurable malignancy and novel treatments are still desperately needed …
[HTML][HTML] Daratumumab in dialysis-dependent multiple myeloma
P Jeyaraman, A Bhasin, N Dayal, S Pathak… - Blood …, 2020 - synapse.koreamed.org
TO THE EDITOR: Daratumumab is an IgG1 kappa monoclonal antibody against CD38,
overexpressed by myeloma cells. It acts by several mechanisms, including triggering …
overexpressed by myeloma cells. It acts by several mechanisms, including triggering …
[HTML][HTML] Rapid infusion daratumumab is safe and well tolerated in clinical practice
IS Hamadeh, J Arnall, E Kachur, A Martin, MH Jagosky… - Blood, 2018 - Elsevier
Introduction: Daratumumab is an anti-CD38 monoclonal antibody, currently FDA approved
for treatment of newly diagnosed transplant ineligible multiple myeloma (MM) in combination …
for treatment of newly diagnosed transplant ineligible multiple myeloma (MM) in combination …
Results of an early access treatment protocol of daratumumab monotherapy in Spanish patients with relapsed or refractory multiple myeloma
A Alegre, J de la Rubia, A Sureda Balari… - …, 2020 - Wiley Online Library
Daratumumab is a human CD38‐targeted monoclonal antibody approved as monotherapy
for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the …
for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the …
Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU
K McKeage, KA Lyseng-Williamson - Drugs & Therapy Perspectives, 2016 - Springer
Daratumumab (Darzalex™) is a first-in-class, human immunoglobulin G1 kappa monoclonal
antibody that targets the CD38 epitope that is highly expressed on the surface of multiple …
antibody that targets the CD38 epitope that is highly expressed on the surface of multiple …